APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vascular Protective Agents

Compare research editions
View pricing & licenses

Selected research

Industry Research

Vascular Protective Agents Industry Research Report 2026

27 December 2025142 pages

Choose your research edition.

Industry ResearchVascular Protective Agents Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Vascular Protective Agents Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Vascular Protective Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vascular Protective Agents Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Vascular Protective Agents Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Vascular Protective Agents market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Vascular Protective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Vascular Protective Agents is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Vascular Protective Agents is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Vascular Protective Agents include Chongqing Huasen Pharmaceutical Co., Ltd., Yantai Dongcheng Pharmaceutical Group Co., Ltd., Xi'an Janssen Pharmaceutical Co., Ltd., Wuhan Aimin Pharmaceutical Co., Ltd., Tonghua Xindongri Pharmaceutical Co., Ltd., Sichuan Xieli Pharmaceutical Co., Ltd., Sichuan Feideli Pharmaceutical Co., Ltd., Shanxi Huakang Pharmaceutical Co., Ltd. and Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Vascular Protective Agents market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Vascular Protective Agents Market by Company

Chongqing Huasen Pharmaceutical Co., Ltd.

Yantai Dongcheng Pharmaceutical Group Co., Ltd.

Xi'an Janssen Pharmaceutical Co., Ltd.

Wuhan Aimin Pharmaceutical Co., Ltd.

Tonghua Xindongri Pharmaceutical Co., Ltd.

Sichuan Xieli Pharmaceutical Co., Ltd.

Sichuan Feideli Pharmaceutical Co., Ltd.

Shanxi Huakang Pharmaceutical Co., Ltd.

Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.

Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.

Mayinglong Pharmaceutical Group Co., Ltd.

Jilin Jinsheng Pharmaceutical Co., Ltd.

Hunan Yige Pharmaceutical Co., Ltd.

Hubei Keyi Pharmaceutical Co., Ltd.

Guangxi Hercules Pharmaceutical Co., Ltd.

Chengdu Yazhong Biopharmaceutical Co., Ltd.

Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.

STELLA

Stanex

Sebela Pharmaceuticals Inc.

Pfizer

Manus Aktteva Biopharma LLP

Hepac

Globela Pharma

Bioiberica

Advacare Pharma

Vascular Protective Agents Segment by Type

Diosmin (Citrus Flavonoids)

Polysaccharide Polysulfate

Complex Carrageenan Esters

Heparin

Aescin

Trexerutin

Vascular Protective Agents Segment by Application

Hospital

Clinic

Other

Vascular Protective Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vascular Protective Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vascular Protective Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vascular Protective Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Vascular Protective Agents manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Vascular Protective Agents by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Vascular Protective Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Vascular Protective Agents Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Vascular Protective Agents Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Vascular Protective Agents Sales Market Share by Manufacturers (2021-2026) Table 8. Global Vascular Protective Agents Revenue of Manufacturers (2021-2026) Table 9. Global Vascular Protective Agents Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Vascular Protective Agents Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Vascular Protective Agents Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Vascular Protective Agents, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Vascular Protective Agents, Product Type & Application Table 14. Global Vascular Protective Agents Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Vascular Protective Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Chongqing Huasen Pharmaceutical Co., Ltd. Company Information Table 19. Chongqing Huasen Pharmaceutical Co., Ltd. Business Overview Table 20. Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 22. Chongqing Huasen Pharmaceutical Co., Ltd. Recent Developments Table 23. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Company Information Table 24. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Business Overview Table 25. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio Table 27. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Recent Developments Table 28. Xi'an Janssen Pharmaceutical Co., Ltd. Company Information Table 29. Xi'an Janssen Pharmaceutical Co., Ltd. Business Overview Table 30. Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 32. Xi'an Janssen Pharmaceutical Co., Ltd. Recent Developments Table 33. Wuhan Aimin Pharmaceutical Co., Ltd. Company Information Table 34. Wuhan Aimin Pharmaceutical Co., Ltd. Business Overview Table 35. Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 37. Wuhan Aimin Pharmaceutical Co., Ltd. Recent Developments Table 38. Tonghua Xindongri Pharmaceutical Co., Ltd. Company Information Table 39. Tonghua Xindongri Pharmaceutical Co., Ltd. Business Overview Table 40. Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 42. Tonghua Xindongri Pharmaceutical Co., Ltd. Recent Developments Table 43. Sichuan Xieli Pharmaceutical Co., Ltd. Company Information Table 44. Sichuan Xieli Pharmaceutical Co., Ltd. Business Overview Table 45. Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 47. Sichuan Xieli Pharmaceutical Co., Ltd. Recent Developments Table 48. Sichuan Feideli Pharmaceutical Co., Ltd. Company Information Table 49. Sichuan Feideli Pharmaceutical Co., Ltd. Business Overview Table 50. Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 52. Sichuan Feideli Pharmaceutical Co., Ltd. Recent Developments Table 53. Shanxi Huakang Pharmaceutical Co., Ltd. Company Information Table 54. Shanxi Huakang Pharmaceutical Co., Ltd. Business Overview Table 55. Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 57. Shanxi Huakang Pharmaceutical Co., Ltd. Recent Developments Table 58. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Company Information Table 59. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Business Overview Table 60. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 62. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Recent Developments Table 63. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Company Information Table 64. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Business Overview Table 65. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 67. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Recent Developments Table 68. Mayinglong Pharmaceutical Group Co., Ltd. Company Information Table 69. Mayinglong Pharmaceutical Group Co., Ltd. Business Overview Table 70. Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio Table 72. Mayinglong Pharmaceutical Group Co., Ltd. Recent Developments Table 73. Jilin Jinsheng Pharmaceutical Co., Ltd. Company Information Table 74. Jilin Jinsheng Pharmaceutical Co., Ltd. Business Overview Table 75. Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 77. Jilin Jinsheng Pharmaceutical Co., Ltd. Recent Developments Table 78. Hunan Yige Pharmaceutical Co., Ltd. Company Information Table 79. Hunan Yige Pharmaceutical Co., Ltd. Business Overview Table 80. Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 82. Hunan Yige Pharmaceutical Co., Ltd. Recent Developments Table 83. Hubei Keyi Pharmaceutical Co., Ltd. Company Information Table 84. Hubei Keyi Pharmaceutical Co., Ltd. Business Overview Table 85. Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 87. Hubei Keyi Pharmaceutical Co., Ltd. Recent Developments Table 88. Guangxi Hercules Pharmaceutical Co., Ltd. Company Information Table 89. Guangxi Hercules Pharmaceutical Co., Ltd. Business Overview Table 90. Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 92. Guangxi Hercules Pharmaceutical Co., Ltd. Recent Developments Table 93. Chengdu Yazhong Biopharmaceutical Co., Ltd. Company Information Table 94. Chengdu Yazhong Biopharmaceutical Co., Ltd. Business Overview Table 95. Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 97. Chengdu Yazhong Biopharmaceutical Co., Ltd. Recent Developments Table 98. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Company Information Table 99. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Business Overview Table 100. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 102. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Recent Developments Table 103. STELLA Company Information Table 104. STELLA Business Overview Table 105. STELLA Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. STELLA Vascular Protective Agents Product Portfolio Table 107. STELLA Recent Developments Table 108. Stanex Company Information Table 109. Stanex Business Overview Table 110. Stanex Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Stanex Vascular Protective Agents Product Portfolio Table 112. Stanex Recent Developments Table 113. Sebela Pharmaceuticals Inc. Company Information Table 114. Sebela Pharmaceuticals Inc. Business Overview Table 115. Sebela Pharmaceuticals Inc. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Sebela Pharmaceuticals Inc. Vascular Protective Agents Product Portfolio Table 117. Sebela Pharmaceuticals Inc. Recent Developments Table 118. Pfizer Company Information Table 119. Pfizer Business Overview Table 120. Pfizer Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Pfizer Vascular Protective Agents Product Portfolio Table 122. Pfizer Recent Developments Table 123. Manus Aktteva Biopharma LLP Company Information Table 124. Manus Aktteva Biopharma LLP Business Overview Table 125. Manus Aktteva Biopharma LLP Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Manus Aktteva Biopharma LLP Vascular Protective Agents Product Portfolio Table 127. Manus Aktteva Biopharma LLP Recent Developments Table 128. Hepac Company Information Table 129. Hepac Business Overview Table 130. Hepac Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Hepac Vascular Protective Agents Product Portfolio Table 132. Hepac Recent Developments Table 133. Globela Pharma Company Information Table 134. Globela Pharma Business Overview Table 135. Globela Pharma Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Globela Pharma Vascular Protective Agents Product Portfolio Table 137. Globela Pharma Recent Developments Table 138. Bioiberica Company Information Table 139. Bioiberica Business Overview Table 140. Bioiberica Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Bioiberica Vascular Protective Agents Product Portfolio Table 142. Bioiberica Recent Developments Table 143. Advacare Pharma Company Information Table 144. Advacare Pharma Business Overview Table 145. Advacare Pharma Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Advacare Pharma Vascular Protective Agents Product Portfolio Table 147. Advacare Pharma Recent Developments Table 148. Global Vascular Protective Agents Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 149. Global Vascular Protective Agents Sales by Region (2021-2026) & (K Units) Table 150. Global Vascular Protective Agents Sales Market Share by Region (2021-2026) Table 151. Global Vascular Protective Agents Sales by Region (2027-2032) & (K Units) Table 152. Global Vascular Protective Agents Sales Market Share by Region (2027-2032) Table 153. Global Vascular Protective Agents Revenue by Region (2021-2026) & (US$ Million) Table 154. Global Vascular Protective Agents Revenue Market Share by Region (2021-2026) Table 155. Global Vascular Protective Agents Revenue by Region (2027-2032) & (US$ Million) Table 156. Global Vascular Protective Agents Revenue Market Share by Region (2027-2032) Table 157. North America Vascular Protective Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. North America Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 159. North America Vascular Protective Agents Sales by Country (2027-2032) & (K Units) Table 160. North America Vascular Protective Agents Revenue by Country (2021-2026) & (US$ Million) Table 161. North America Vascular Protective Agents Revenue by Country (2027-2032) & (US$ Million) Table 162. Europe Vascular Protective Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. Europe Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 164. Europe Vascular Protective Agents Sales by Country (2027-2032) & (K Units) Table 165. Europe Vascular Protective Agents Revenue by Country (2021-2026) & (US$ Million) Table 166. Europe Vascular Protective Agents Revenue by Country (2027-2032) & (US$ Million) Table 167. Asia Pacific Vascular Protective Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. Asia Pacific Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 169. Asia Pacific Vascular Protective Agents Sales by Country (2027-2032) & (K Units) Table 170. Asia Pacific Vascular Protective Agents Revenue by Country (2021-2026) & (US$ Million) Table 171. Asia Pacific Vascular Protective Agents Revenue by Country (2027-2032) & (US$ Million) Table 172. South America Vascular Protective Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 173. South America Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 174. South America Vascular Protective Agents Sales by Country (2027-2032) & (K Units) Table 175. South America Vascular Protective Agents Revenue by Country (2021-2026) & (US$ Million) Table 176. South America Vascular Protective Agents Revenue by Country (2027-2032) & (US$ Million) Table 177. Middle East and Africa Vascular Protective Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 178. Middle East and Africa Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 179. Middle East and Africa Vascular Protective Agents Sales by Country (2027-2032) & (K Units) Table 180. Middle East and Africa Vascular Protective Agents Revenue by Country (2021-2026) & (US$ Million) Table 181. Middle East and Africa Vascular Protective Agents Revenue by Country (2027-2032) & (US$ Million) Table 182. Global Vascular Protective Agents Sales by Type (2021-2026) & (K Units) Table 183. Global Vascular Protective Agents Sales by Type (2027-2032) & (K Units) Table 184. Global Vascular Protective Agents Sales Market Share by Type (2021-2026) Table 185. Global Vascular Protective Agents Sales Market Share by Type (2027-2032) Table 186. Global Vascular Protective Agents Revenue by Type (2021-2026) & (US$ Million) Table 187. Global Vascular Protective Agents Revenue by Type (2027-2032) & (US$ Million) Table 188. Global Vascular Protective Agents Revenue Market Share by Type (2021-2026) Table 189. Global Vascular Protective Agents Revenue Market Share by Type (2027-2032) Table 190. Global Vascular Protective Agents Price by Type (2021-2026) & (US$/Unit) Table 191. Global Vascular Protective Agents Price by Type (2027-2032) & (US$/Unit) Table 192. Global Vascular Protective Agents Sales by Application (2021-2026) & (K Units) Table 193. Global Vascular Protective Agents Sales by Application (2027-2032) & (K Units) Table 194. Global Vascular Protective Agents Sales Market Share by Application (2021-2026) Table 195. Global Vascular Protective Agents Sales Market Share by Application (2027-2032) Table 196. Global Vascular Protective Agents Revenue by Application (2021-2026) & (US$ Million) Table 197. Global Vascular Protective Agents Revenue by Application (2027-2032) & (US$ Million) Table 198. Global Vascular Protective Agents Revenue Market Share by Application (2021-2026) Table 199. Global Vascular Protective Agents Revenue Market Share by Application (2027-2032) Table 200. Global Vascular Protective Agents Price by Application (2021-2026) & (US$/Unit) Table 201. Global Vascular Protective Agents Price by Application (2027-2032) & (US$/Unit) Table 202. Key Raw Materials Table 203. Raw Materials Key Suppliers Table 204. Vascular Protective Agents Distributors List Table 205. Vascular Protective Agents Customers List Table 206. Vascular Protective Agents Industry Trends Table 207. Vascular Protective Agents Industry Drivers Table 208. Vascular Protective Agents Industry Restraints Table 209. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Vascular Protective Agents Product Image Figure 5. Global Vascular Protective Agents Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Vascular Protective Agents Market Size (2021-2032) & (US$ Million) Figure 7. Global Vascular Protective Agents Sales (2021-2032) & (K Units) Figure 8. Global Vascular Protective Agents Average Price (US$/Unit) & (2021-2032) Figure 9. Diosmin (Citrus Flavonoids) Product Image Figure 10. Polysaccharide Polysulfate Product Image Figure 11. Complex Carrageenan Esters Product Image Figure 12. Heparin Product Image Figure 13. Aescin Product Image Figure 14. Trexerutin Product Image Figure 15. Hospital Product Image Figure 16. Clinic Product Image Figure 17. Other Product Image Figure 18. Global Vascular Protective Agents Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Vascular Protective Agents, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Vascular Protective Agents Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Vascular Protective Agents Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Vascular Protective Agents Sales by Region in 2025 Figure 24. Global Vascular Protective Agents Revenue by Region in 2025 Figure 25. North America Vascular Protective Agents Market Size by Country in 2025 Figure 26. North America Vascular Protective Agents Sales Market Share by Country (2021-2032) Figure 27. North America Vascular Protective Agents Revenue Market Share by Country (2021-2032) Figure 28. United States Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Vascular Protective Agents Market Size by Country in 2025 Figure 32. Europe Vascular Protective Agents Sales Market Share by Country (2021-2032) Figure 33. Europe Vascular Protective Agents Revenue Market Share by Country (2021-2032) Figure 34. Germany Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Vascular Protective Agents Market Size by Country in 2025 Figure 45. Asia Pacific Vascular Protective Agents Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Vascular Protective Agents Revenue Market Share by Country (2021-2032) Figure 47. China Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Vascular Protective Agents Market Size by Country in 2025 Figure 56. South America Vascular Protective Agents Sales Market Share by Country (2021-2032) Figure 57. South America Vascular Protective Agents Revenue Market Share by Country (2021-2032) Figure 58. Brazil Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Vascular Protective Agents Market Size by Country in 2025 Figure 62. Middle East and Africa Vascular Protective Agents Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Vascular Protective Agents Revenue Market Share by Country (2021-2032) Figure 64. Egypt Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Vascular Protective Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Vascular Protective Agents Sales Market Share by Type (2021-2032) Figure 70. Global Vascular Protective Agents Revenue Market Share by Type (2021-2032) Figure 71. Global Vascular Protective Agents Price (US$/Unit) by Type (2021-2032) Figure 72. Global Vascular Protective Agents Sales Market Share by Application (2021-2032) Figure 73. Global Vascular Protective Agents Revenue Market Share by Application (2021-2032) Figure 74. Global Vascular Protective Agents Price (US$/Unit) by Application (2021-2032) Figure 75. Vascular Protective Agents Value Chain Figure 76. Vascular Protective Agents Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Vascular Protective Agents Industry Opportunities and Challenges

Scope & coverage.

Types
  • Diosmin (Citrus Flavonoids)
  • Polysaccharide Polysulfate
  • Complex Carrageenan Esters
  • Heparin
  • Aescin
  • Trexerutin
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Chongqing Huasen Pharmaceutical Co., Ltd.
  • Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • Xi'an Janssen Pharmaceutical Co., Ltd.
  • Wuhan Aimin Pharmaceutical Co., Ltd.
  • Tonghua Xindongri Pharmaceutical Co., Ltd.
  • Sichuan Xieli Pharmaceutical Co., Ltd.
  • Sichuan Feideli Pharmaceutical Co., Ltd.
  • Shanxi Huakang Pharmaceutical Co., Ltd.
  • Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.
  • Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
  • Mayinglong Pharmaceutical Group Co., Ltd.
  • Jilin Jinsheng Pharmaceutical Co., Ltd.
  • Hunan Yige Pharmaceutical Co., Ltd.
  • Hubei Keyi Pharmaceutical Co., Ltd.
  • Guangxi Hercules Pharmaceutical Co., Ltd.
  • Chengdu Yazhong Biopharmaceutical Co., Ltd.
  • Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
  • STELLA
  • Stanex
  • Sebela Pharmaceuticals Inc.
  • Pfizer
  • Manus Aktteva Biopharma LLP
  • Hepac
  • Globela Pharma
  • Bioiberica
  • Advacare Pharma

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Vascular Protective Agents Market Size (2021-2032)
  4. 2.2.2 Global Vascular Protective Agents Sales (2021-2032)
  5. 2.2.3 Global Vascular Protective Agents Market Average Price (2021-2032)
  6. 2.3 Vascular Protective Agents by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Diosmin (Citrus Flavonoids)
  9. 2.3.3 Polysaccharide Polysulfate
  10. 2.3.4 Complex Carrageenan Esters
  11. 2.3.5 Heparin
  12. 2.3.6 Aescin
  13. 2.3.7 Trexerutin
  14. 2.4 Vascular Protective Agents by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Hospital
  17. 2.4.3 Clinic
  18. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Vascular Protective Agents Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Vascular Protective Agents Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Vascular Protective Agents Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Vascular Protective Agents Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Vascular Protective Agents Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Vascular Protective Agents, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Vascular Protective Agents, Product Type & Application
  8. 3.8 Global Manufacturers of Vascular Protective Agents, Established Date
  9. 3.9 Global Vascular Protective Agents Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chongqing Huasen Pharmaceutical Co., Ltd.
  2. 4.1.1 Chongqing Huasen Pharmaceutical Co., Ltd. Company Information
  3. 4.1.2 Chongqing Huasen Pharmaceutical Co., Ltd. Business Overview
  4. 4.1.3 Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  6. 4.1.5 Chongqing Huasen Pharmaceutical Co., Ltd. Recent Developments
  7. 4.2 Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  8. 4.2.1 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Company Information
  9. 4.2.2 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Business Overview
  10. 4.2.3 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio
  12. 4.2.5 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Recent Developments
  13. 4.3 Xi'an Janssen Pharmaceutical Co., Ltd.
  14. 4.3.1 Xi'an Janssen Pharmaceutical Co., Ltd. Company Information
  15. 4.3.2 Xi'an Janssen Pharmaceutical Co., Ltd. Business Overview
  16. 4.3.3 Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  18. 4.3.5 Xi'an Janssen Pharmaceutical Co., Ltd. Recent Developments
  19. 4.4 Wuhan Aimin Pharmaceutical Co., Ltd.
  20. 4.4.1 Wuhan Aimin Pharmaceutical Co., Ltd. Company Information
  21. 4.4.2 Wuhan Aimin Pharmaceutical Co., Ltd. Business Overview
  22. 4.4.3 Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  24. 4.4.5 Wuhan Aimin Pharmaceutical Co., Ltd. Recent Developments
  25. 4.5 Tonghua Xindongri Pharmaceutical Co., Ltd.
  26. 4.5.1 Tonghua Xindongri Pharmaceutical Co., Ltd. Company Information
  27. 4.5.2 Tonghua Xindongri Pharmaceutical Co., Ltd. Business Overview
  28. 4.5.3 Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  30. 4.5.5 Tonghua Xindongri Pharmaceutical Co., Ltd. Recent Developments
  31. 4.6 Sichuan Xieli Pharmaceutical Co., Ltd.
  32. 4.6.1 Sichuan Xieli Pharmaceutical Co., Ltd. Company Information
  33. 4.6.2 Sichuan Xieli Pharmaceutical Co., Ltd. Business Overview
  34. 4.6.3 Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  36. 4.6.5 Sichuan Xieli Pharmaceutical Co., Ltd. Recent Developments
  37. 4.7 Sichuan Feideli Pharmaceutical Co., Ltd.
  38. 4.7.1 Sichuan Feideli Pharmaceutical Co., Ltd. Company Information
  39. 4.7.2 Sichuan Feideli Pharmaceutical Co., Ltd. Business Overview
  40. 4.7.3 Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  42. 4.7.5 Sichuan Feideli Pharmaceutical Co., Ltd. Recent Developments
  43. 4.8 Shanxi Huakang Pharmaceutical Co., Ltd.
  44. 4.8.1 Shanxi Huakang Pharmaceutical Co., Ltd. Company Information
  45. 4.8.2 Shanxi Huakang Pharmaceutical Co., Ltd. Business Overview
  46. 4.8.3 Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  48. 4.8.5 Shanxi Huakang Pharmaceutical Co., Ltd. Recent Developments
  49. 4.9 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.
  50. 4.9.1 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Company Information
  51. 4.9.2 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Business Overview
  52. 4.9.3 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  54. 4.9.5 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Recent Developments
  55. 4.10 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
  56. 4.10.1 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Company Information
  57. 4.10.2 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Business Overview
  58. 4.10.3 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  60. 4.10.5 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Recent Developments
  61. 4.11 Mayinglong Pharmaceutical Group Co., Ltd.
  62. 4.11.1 Mayinglong Pharmaceutical Group Co., Ltd. Company Information
  63. 4.11.2 Mayinglong Pharmaceutical Group Co., Ltd. Business Overview
  64. 4.11.3 Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio
  66. 4.11.5 Mayinglong Pharmaceutical Group Co., Ltd. Recent Developments
  67. 4.12 Jilin Jinsheng Pharmaceutical Co., Ltd.
  68. 4.12.1 Jilin Jinsheng Pharmaceutical Co., Ltd. Company Information
  69. 4.12.2 Jilin Jinsheng Pharmaceutical Co., Ltd. Business Overview
  70. 4.12.3 Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  72. 4.12.5 Jilin Jinsheng Pharmaceutical Co., Ltd. Recent Developments
  73. 4.13 Hunan Yige Pharmaceutical Co., Ltd.
  74. 4.13.1 Hunan Yige Pharmaceutical Co., Ltd. Company Information
  75. 4.13.2 Hunan Yige Pharmaceutical Co., Ltd. Business Overview
  76. 4.13.3 Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  78. 4.13.5 Hunan Yige Pharmaceutical Co., Ltd. Recent Developments
  79. 4.14 Hubei Keyi Pharmaceutical Co., Ltd.
  80. 4.14.1 Hubei Keyi Pharmaceutical Co., Ltd. Company Information
  81. 4.14.2 Hubei Keyi Pharmaceutical Co., Ltd. Business Overview
  82. 4.14.3 Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  84. 4.14.5 Hubei Keyi Pharmaceutical Co., Ltd. Recent Developments
  85. 4.15 Guangxi Hercules Pharmaceutical Co., Ltd.
  86. 4.15.1 Guangxi Hercules Pharmaceutical Co., Ltd. Company Information
  87. 4.15.2 Guangxi Hercules Pharmaceutical Co., Ltd. Business Overview
  88. 4.15.3 Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  90. 4.15.5 Guangxi Hercules Pharmaceutical Co., Ltd. Recent Developments
  91. 4.16 Chengdu Yazhong Biopharmaceutical Co., Ltd.
  92. 4.16.1 Chengdu Yazhong Biopharmaceutical Co., Ltd. Company Information
  93. 4.16.2 Chengdu Yazhong Biopharmaceutical Co., Ltd. Business Overview
  94. 4.16.3 Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  96. 4.16.5 Chengdu Yazhong Biopharmaceutical Co., Ltd. Recent Developments
  97. 4.17 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
  98. 4.17.1 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Company Information
  99. 4.17.2 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Business Overview
  100. 4.17.3 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  102. 4.17.5 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Recent Developments
  103. 4.18 STELLA
  104. 4.18.1 STELLA Company Information
  105. 4.18.2 STELLA Business Overview
  106. 4.18.3 STELLA Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 STELLA Vascular Protective Agents Product Portfolio
  108. 4.18.5 STELLA Recent Developments
  109. 4.19 Stanex
  110. 4.19.1 Stanex Company Information
  111. 4.19.2 Stanex Business Overview
  112. 4.19.3 Stanex Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Stanex Vascular Protective Agents Product Portfolio
  114. 4.19.5 Stanex Recent Developments
  115. 4.20 Sebela Pharmaceuticals Inc.
  116. 4.20.1 Sebela Pharmaceuticals Inc. Company Information
  117. 4.20.2 Sebela Pharmaceuticals Inc. Business Overview
  118. 4.20.3 Sebela Pharmaceuticals Inc. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Sebela Pharmaceuticals Inc. Vascular Protective Agents Product Portfolio
  120. 4.20.5 Sebela Pharmaceuticals Inc. Recent Developments
  121. 4.21 Pfizer
  122. 4.21.1 Pfizer Company Information
  123. 4.21.2 Pfizer Business Overview
  124. 4.21.3 Pfizer Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Pfizer Vascular Protective Agents Product Portfolio
  126. 4.21.5 Pfizer Recent Developments
  127. 4.22 Manus Aktteva Biopharma LLP
  128. 4.22.1 Manus Aktteva Biopharma LLP Company Information
  129. 4.22.2 Manus Aktteva Biopharma LLP Business Overview
  130. 4.22.3 Manus Aktteva Biopharma LLP Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Manus Aktteva Biopharma LLP Vascular Protective Agents Product Portfolio
  132. 4.22.5 Manus Aktteva Biopharma LLP Recent Developments
  133. 4.23 Hepac
  134. 4.23.1 Hepac Company Information
  135. 4.23.2 Hepac Business Overview
  136. 4.23.3 Hepac Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Hepac Vascular Protective Agents Product Portfolio
  138. 4.23.5 Hepac Recent Developments
  139. 4.24 Globela Pharma
  140. 4.24.1 Globela Pharma Company Information
  141. 4.24.2 Globela Pharma Business Overview
  142. 4.24.3 Globela Pharma Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Globela Pharma Vascular Protective Agents Product Portfolio
  144. 4.24.5 Globela Pharma Recent Developments
  145. 4.25 Bioiberica
  146. 4.25.1 Bioiberica Company Information
  147. 4.25.2 Bioiberica Business Overview
  148. 4.25.3 Bioiberica Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Bioiberica Vascular Protective Agents Product Portfolio
  150. 4.25.5 Bioiberica Recent Developments
  151. 4.26 Advacare Pharma
  152. 4.26.1 Advacare Pharma Company Information
  153. 4.26.2 Advacare Pharma Business Overview
  154. 4.26.3 Advacare Pharma Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  155. 4.26.4 Advacare Pharma Vascular Protective Agents Product Portfolio
  156. 4.26.5 Advacare Pharma Recent Developments
5 Global Vascular Protective Agents Market Scenario by Region
  1. 5.1 Global Vascular Protective Agents Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Vascular Protective Agents Sales by Region: 2021-2032
  3. 5.2.1 Global Vascular Protective Agents Sales by Region: 2021-2026
  4. 5.2.2 Global Vascular Protective Agents Sales by Region: 2027-2032
  5. 5.3 Global Vascular Protective Agents Revenue by Region: 2021-2032
  6. 5.3.1 Global Vascular Protective Agents Revenue by Region: 2021-2026
  7. 5.3.2 Global Vascular Protective Agents Revenue by Region: 2027-2032
  8. 5.4 North America Vascular Protective Agents Market Facts & Figures by Country
  9. 5.4.1 North America Vascular Protective Agents Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Vascular Protective Agents Sales by Country (2021-2032)
  11. 5.4.3 North America Vascular Protective Agents Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Vascular Protective Agents Market Facts & Figures by Country
  16. 5.5.1 Europe Vascular Protective Agents Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Vascular Protective Agents Sales by Country (2021-2032)
  18. 5.5.3 Europe Vascular Protective Agents Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Vascular Protective Agents Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Vascular Protective Agents Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Vascular Protective Agents Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Vascular Protective Agents Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Vascular Protective Agents Market Facts & Figures by Country
  41. 5.7.1 South America Vascular Protective Agents Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Vascular Protective Agents Sales by Country (2021-2032)
  43. 5.7.3 South America Vascular Protective Agents Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Vascular Protective Agents Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Vascular Protective Agents Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Vascular Protective Agents Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Vascular Protective Agents Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Vascular Protective Agents Sales by Type (2021-2032)
  2. 6.1.1 Global Vascular Protective Agents Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Vascular Protective Agents Sales Market Share by Type (2021-2032)
  4. 6.2 Global Vascular Protective Agents Revenue by Type (2021-2032)
  5. 6.2.1 Global Vascular Protective Agents Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Vascular Protective Agents Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Vascular Protective Agents Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Vascular Protective Agents Sales by Application (2021-2032)
  2. 7.1.1 Global Vascular Protective Agents Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Vascular Protective Agents Sales Market Share by Application (2021-2032)
  4. 7.2 Global Vascular Protective Agents Revenue by Application (2021-2032)
  5. 7.2.1 Global Vascular Protective Agents Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Vascular Protective Agents Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Vascular Protective Agents Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Vascular Protective Agents Value Chain Analysis
  2. 8.1.1 Vascular Protective Agents Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Vascular Protective Agents Production Mode & Process
  5. 8.2 Vascular Protective Agents Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Vascular Protective Agents Distributors
  8. 8.2.3 Vascular Protective Agents Customers
9 Global Vascular Protective Agents Analyzing Market Dynamics
  1. 9.1 Vascular Protective Agents Industry Trends
  2. 9.2 Vascular Protective Agents Industry Drivers
  3. 9.3 Vascular Protective Agents Industry Opportunities and Challenges
  4. 9.4 Vascular Protective Agents Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst